1. Home
  2. HWH vs NOTV Comparison

HWH vs NOTV Comparison

Compare HWH & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HWH International Inc.

HWH

HWH International Inc.

HOLD

Current Price

$1.68

Market Cap

9.8M

Sector

Health Care

ML Signal

HOLD

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.08

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWH
NOTV
Founded
2021
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
10.8M
IPO Year
2022
1997

Fundamental Metrics

Financial Performance
Metric
HWH
NOTV
Price
$1.68
$0.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
743.1K
66.5M
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
47.37
49.64
EPS
N/A
N/A
Revenue
$866,926.00
$547,656,000.00
Revenue This Year
N/A
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$0.88
$0.08
52 Week High
$7.77
$2.44

Technical Indicators

Market Signals
Indicator
HWH
NOTV
Relative Strength Index (RSI) 75.77 31.45
Support Level $1.00 N/A
Resistance Level $1.85 $0.33
Average True Range (ATR) 0.22 0.04
MACD 0.08 -0.02
Stochastic Oscillator 42.50 0.70

Price Performance

Historical Comparison
HWH
NOTV

About HWH HWH International Inc.

HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: